|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01513 LIVZON PHARMA
Nominal 
26.850 +0.450 (+1.705%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 12,430,038 | -1.580% | 12,629,579 | 12,063,863 | 10,520,410 | 9,384,696 |
| Cost of Sales | -- | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- | -- |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (348,754) | 76.511% | (197,582) | (87,342) | (64,750) | (56,756) | |
| Profit / (Loss) on Disposal | (170) | -- | 861 | 7,035 | (1,072) | 460 | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 58,461 | -4.479% | 61,202 | 39,064 | 1,907 | (10,686) | |
| Profit / (Loss) before Taxation | 2,382,667 | 2.236% | 2,330,551 | 2,245,689 | 2,489,436 | 1,727,542 | |
| Taxation | (485,066) | 29.360% | (374,973) | (293,588) | (358,109) | (265,965) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 56,050 | -- | (46,170) | (176,418) | (416,416) | (158,702) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 1,953,651 | 2.317% | 1,909,408 | 1,775,683 | 1,714,910 | 1,302,875 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (271,502) | 1.020% | (268,761) | (70,041) | (103,639) | (220,799) |
| Depreciation & Amortisation | 887,900 | 29.501% | 685,630 | 471,339 | 423,391 | 415,495 |
| Directors' Emoluments | 18,324 | -2.021% | 18,702 | 19,795 | 17,177 | 15,859 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | 210.000 | 2.941% | 204.000 | 190.000 | 183.000 | 139.000 |
| DPS (cts) | 135.000 | -- | 160.000 | 130.000 | 125.000 | 115.000 |
| Dividend Payout Ratio (%) | 64.286% | -- | 78.431% | 68.421% | 68.306% | 82.734% |
| Cash flow per share ($) | 3.497 | -- | 2.965 | 2.034 | 2.308 | 1.890 |
| NBV per share ($) | 15.199 | -- | 14.832 | 13.865 | 12.814 | 11.946 |
| Remarks: | Real time quote last updated: 05/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 1,170,971 |
| %Change | 3.208% |
| EPS / (LPS) | RMB 1.270 |
| NBV Per Share (¥) | RMB 15.027 |